Moody Aldrich Partners LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 57.3% during the 4th quarter, HoldingsChannel reports. The fund owned 52,146 shares of the company’s stock after selling 70,115 shares during the period. Moody Aldrich Partners LLC’s holdings in Axsome Therapeutics were worth $4,022,000 at the end […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) shares traded down 4.3% on Tuesday . The stock traded as low as $60.85 and last traded at $61.17. 250,168 shares changed hands during trading, a decline of 74% from the average session volume of 961,231 shares. The stock had previously closed at $63.92. Wall Street Analyst Weigh […]
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its target price reduced by HC Wainwright from $210.00 to $200.00 in a report released on Monday morning, The Fly reports. HC Wainwright also issued estimates for Axsome Therapeutics’ Q1 2023 earnings at ($1.40) EPS, Q2 2023 earnings at ($1.40) EPS, Q3 2023 earnings at ($1.29) EPS, Q4 […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – HC Wainwright reduced their Q1 2023 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, March 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.40) for the quarter, down […]
Stock analysts at StockNews.com assumed coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock. AXSM has been the topic of a number of other reports. Morgan Stanley dropped their price objective on shares of Axsome Therapeutics from $86.00 […]